Teva- Pharmaceutical Industries Long Term Debt

Teva- Pharmaceutical Industries (TEVA) currently reports a long-term debt of $12B as of June 2026. That compares with $17B in the prior-year period — down 27.5% year over year. Use the charts on this page to explore Teva- Pharmaceutical Industries's long-term debt history and peer comparisons.

Teva- Pharmaceutical Industries's long-term debt decreased from $17B to $12B — a 27.5% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Teva- Pharmaceutical Industries reported $12B in long-term debt as of June 2026. That compares with $17B in the prior-year period — down 27.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $12B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Teva- Pharmaceutical Industries, and consider following TEVA for alerts when major investors trade the stock.

Teva- Pharmaceutical Industries is classified in the Healthcare sector. On long-term debt, it currently shows $12B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TEVA with unrelated industries.